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Schizophrenia (SCZ) is one of the most severe and devastating major mental disorders, with an onset typically in late 
adolescence or early adulthood affecting about 0.5–1.2% of the population worldwide. It is one of the most debilitating 
medical conditions, with striking socio-economic burden to society due to lost employment and social support that 
largely surpass direct costs of treatment. SCZ is listed by the World Health Organization (WHO) among the top 20 lead-
ing causes of disability worldwide. Its diagnosis is syndromic, based in clinical interviewing and anamnesis, as there is 
to date no biochemical test to aid in this diagnosis. On the other hand, SCZ treatment is mostly based in antipsychotic 
drugs which are in several aspects somehow ineffective, and some of these medications have low tolerability with 
severe side effects.  For all these reasons, the current search for new panels of biomarkers is of the utmost importance 
to aid in the correct diagnosis and stratification of the patients, prognosis, and prediction of treatment effectiveness.
In this review, a total of 25 publications on peripheral SCZ biomarkers are presented from proteomics studies performed 
in body fluids of patients searching for protein markers, and using mass spectrometry. To date such proteomics studies 
have already been achieved in cerebrospinal fluid (CSF), serum, plasma, peripheral blood cells (namely, mononuclear 
cells, T-cells and red blood cells), saliva, and sweat, being of paramount importance in the schizophrenia research field, 
but still lacking validation and clinical translation.
In summary, a general overview of the results from these 25 studies, as well as the challenges and future perspectives 
of the field, are presented and discussed.
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Introduction
Schizophrenia (SCZ) is categorized as a psychotic disorder, 
being one of the more debilitating major mental disorders 
[1]. Its socio-economic burden to society is enormous, 
being listed by the World Health Organization (WHO) 
among the top 20 leading causes of disability worldwide [2].
This disorder is characterized by a chronic and fre-
quently deteriorating course  with a prevalence of 0.5–1.2% 
of the population worldwide [3]. Usually, its onset occurs 
in late adolescence or adulthood, although rare infant and 
late-onset cases have been reported, and is frequently pre-
ceded by a prodromal phase with a variable duration [1, 4].
SCZ has substantial clinical heterogeneity, with con-
siderable symptomatic variation between patients, and is 
characterized by a diverse set of symptoms: (i) positive, 
such as delusions, hallucinations or thought disorder; (ii) 
negative, as affective flattening, reduced interest and mo-
tivation and also social withdrawal; (iii) cognitive dysfunc-
tion symptoms, as impaired attention, learning and mem-
ory; where positive symptoms tend to relapse and remit, 
negative and cognitive symptoms tend to be chronic and 
the main drivers of patients’ poor social functioning [4].
Like many common diseases SCZ is complex and mul-
tifactorial, with contributions from multiple susceptibility 
genetic variants and environmental factors [1]. Yet, stud-
ies of its heritability are complicated by locus heterogene-
ity, imprecise phenotypic definitions, incomplete pene-
trance and interaction with non-genetic factors. Thus, our 
understanding of the pathogenesis and neurobiology of the 
disorder remains fragmented and incomplete.
Diagnosis is only made after a first psychotic episode, 
based in descriptive criteria, and may be considered clini-
cian-dependent as there is to date no biochemical test to 
aid in this diagnosis. On the other hand, SCZ treatment is 
mostly based in antipsychotic drugs which are substantially 
ineffective in about 40% of the patients even in a first epi-
sode; unsurprisingly, around 60% of patients end up quit-
ting treatment due to lack of efficacy and/or severe side ef-
fects [5, 6]. Thus, in the context of current research on the 
pathophysiology of SCZ, the search for new biomarkers, 
especially in body fluids, is of paramount importance to aid 
in the correct diagnosis and stratification of the patients.
In this review, we aim to examine the publications on 
peripheral SCZ biomarkers published until date, in partic-
ular studies on proteomics, searching for protein markers, 
using the leading non-target technique for discovery of the 
field: mass spectrometry. Also, a critical view on the future 
perspectives of the field in what concerns expected results 
and new technical developments are presented.
The need for biomarkers in psychosis
The diagnosis of SCZ is made with information collect-
ed in clinical interviewing, using an unstructured clinical 
approach or by mean of structured diagnostic tools built 
around the criteria of main diagnostic systems. Diagnosis 
is then achieved by verifying the fulfillment of a number of 
operational criteria specified in international classification 
systems such as the Diagnostic and Statistical Manual of 
Mental Disorders, 5th edition (DSM-5)[7] or the Interna-
tional Classification of Diseases, 10th revision (ICD-10) 
[8]. The diagnosis of SCZ remains essentially descriptive 
based on operational criteria that are not pathognomonic 
and whose validity is doubtful. Thus, these criteria cannot 
clearly define the diagnostic boundaries of this nosologic 
entity, demarcating it with certainty from other categories 
of non-affective or even affective psychoses.
In fact, psychiatry remains one of the few areas of med-
icine that does not use routine laboratory tests for diag-
nostic purposes, mainly due to the fact that the biology 
of the diseases is poorly known, their preclinical models 
present many challenges and drawbacks, and specially due 
to the fact that the brain is not easily accessible [9]. Thus, 
schizophrenia remains a syndromic concept with frail va-
lidity, and it has been argued by many that such weakness-
es involving the imprecisions of its diagnostic procedures 
and phenotypic definition have been an impediment for 
research in this area [10].
In psychiatric practice a biomarker (or panel of bio-
markers) may be useful: (i) to correctly diagnose and strat-
ify a psychiatric patient, in a field where several diseases 
may have overlapping clinical symptoms, or even (ii) to 
better classify at-risk individuals; (iii) it may also be used 
for prognosis or (iv) as therapeutic monitoring, and (v) 
predictive of therapy compliance [9, 11, 12]. In summa-
ry, the definition of a biomarker states that it should be 
a quantifiable or identifiable physical characteristic that 
is closely and exclusively related to a given physiological 
state. This way, biomarkers can be used to assess physio-
logical conditions, such as good health or disease, toxicity 
or drug treatment responses [13]. 
Throughout the years many research groups have 
been studying SCZ with numerous and varied strategies. 
In the genetics field studies have been performed using: 
genome wide association studies (GWAS), next-genera-
tion sequencing, copy-number variations (CNV) and mi-
croarrays, with different study designs using the general 
population, twins and family studies [14, 15] linking SCZ 
with rare genetic variations, stating that SCZ has a strong 
genetic component. The heritability is estimated to be 
close to 80%, although the heterogeneous manifestations 
of the disease and its complex genetic architecture indicate 
a non-mendelian complex mode of transmission [15, 16].
Many years and numerous studies later, more than 
100 distinct loci containing fairly common alleles of small 
effect are now known to exist [17]; several copy number 
variants that may individually confer an elevated risk for 
schizophrenia have also been identified [18] (for a review 
on the subject refer to [19]). Thus, it is clear that there is 
a substantial contribution of genetic factors for the patho-
physiology of schizophrenia, but it is also understood that 
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this contribution is not able to fully explain its etiology. 
While the complexity of the subject is well accepted, it is 
believed that much of the genetic risk for schizophrenia 
is still to be uncovered and the majority of genetic find-
ings still do not have a clinical application [1]. Nonetheless 
some authors have already suggested that chromosomal 
microarray analysis of clinically relevant CNVs, with a 
prevalence of around 5%, should be used as a clinical diag-
nostic test [20].
Given all this, a genetic trait associated with schizophre-
nia can give clues about increased risk and susceptibility for 
disease manifestation, but the molecular alterations or defi-
cits are ultimately reflected in the phenotype, as in the pro-
teome and metabolome [11]. The importance of certain en-
vironmental factors and insults are also well established as 
risk factors for schizophrenia [21, 22]. The impact of these 
factors is difficult to anticipate with a genomic analysis, but 
they are reflected in the molecular phenotype. Moreover, 
the genome is static while the proteome and metabolome 
are dynamic [12, 23], making it possible to quantitatively 
track a molecule over time, therefore allowing to evaluate 
disease progression, correlating its levels with symptom se-
verity or anticipating therapeutic outcomes.
Overall, it is possible to state that a need for biomark-
ers of psychiatric diseases at different levels (diagnosis, 
prognosis, treatment resistance…) is pressing and that to 
achieve this not only gene expression and DNA variations 
should be studied and determined, but also the abundance 
and modifications of the proteins and their distribution 
at the subcellular level [14]. In particular, efforts to find 
protein altered patterns in circulating fluids have increased 
interest given that such fluids are relatively easier to ac-
cess than the brain in order to perform clinical testing but, 
firstly, to enable relevant research.
Proteomics contribution for schizophrenia’s 
biomarker research
The term “proteomics” was firstly introduced in 1995 and 
it was used to define the large-scale analysis of the entire 
composition of proteins of a cell line, tissue, or organ-
ism [24]. Proteomics aims to describe and understand 
biological processes based on the qualitative or quantita-
tive comparison of proteomes [14], especially in diseased 
versus control cases. The great development of this area 
may be attributed to the technological advances in mass 
spectrometry (MS), optimization in sample preparation 
and computer sciences that are now able to deal with the 
large amount of information that is nowadays generated 
by the MS-based technologies [25, 26]. With proteomic 
approaches, several levels of information may be obtained: 
(i) identification of the proteins in a sample at a given 
moment; (ii) expression levels of the proteins or quanti-
tative proteomics; (iii) identification or quantification of 
post-translational modifications (PTM) of those proteins 
(phosphorylation, glycosylation, acetylation, …); (iv) de-
termination of protein-protein interactions; (v) proteomic 
functional studies to unravel to role of a protein, constitu-
ents of functional complexes its localization, translocation, 
among others [24, 26].
In the beginning of MS-based large screening pro-
teomic approaches it was possible to characterize proteins 
in complex mixtures, but these studies were mainly quali-
tative; while successfully identifying a high amount of pro-
teins from one sample they fail in quantifying expression 
levels[27]. Over the last few years the proteomics field has 
turned to quantitative approaches, especially due to tech-
nological advances, and this has become the analysis of 
choice when comparing proteomes, given that most of the 
biological changes of interest are slight differences in the 
amount of a protein present in a given situation and not 
an abrupt variation testifying its presence or absence [28].
These improvements in MS-based proteomics tech-
niques have paved the way to reach the long wanted goal of 
having an exhaustive characterization of all proteomes at 
specific moments, especially in diseased states, from where 
biomarkers for diagnosis, prognosis or treatment could be 
identified, validated and introduced into clinical practice. 
This is where the proteomics field stands at the moment, 
being directed to clinical settings although it mainly re-
mains in a discovery phase of biomarkers; in psychiatric 
research the status is not different [23].
The history of proteomics in schizophrenia research 
is very similar to the history of proteomics itself [24, 29]. 
The first reports of untargeted proteomic large screenings 
in schizophrenia begun by using two-dimensional elec-
trophoresis (2-DE) [30] where the first dimension is an 
isoelectric focusing step (IEF) followed by the second di-
mension which is a standard SDS-PAGE. In this approach 
the quantitative information is retrieved from the analy-
sis of the intensity of the staining of a given spot in the 
gel, which is then picked, and the proteins are identified 
by MS. Later on, an improvement of this technology was 
introduced - two-dimensional difference gel electropho-
resis (2D-DIGE) [31], where the separation steps remain 
the same but proteins are directly labelled with fluorescent 
dyes (CyDies), enabling the analysis of multiple samples in 
the same gel, this way improving the reproducibility of the 
quantitative results [32]. 
Although 2-DE techniques have been extremely im-
portant in transforming protein analysis into an “omics” 
approach, these methods have some drawbacks as the 
lengthy sample preparation and difficulty in detecting 
some subtypes of proteins, like membrane proteins, or due 
to dynamic range limitations [32]. Throughout the years 
researchers have turned to other methodologies that can 
measure quantitative levels of the entire set of proteins, 
and that can be divided into two main groups: (i) label-
ling techniques, which require the chemical, metabolic or 
enzymatic stable isotopic labelling of the samples prior to 
MS analysis; (ii) label-free techniques, which are gaining 
increasing interest due to improvements in accuracy and 
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sensitivity of MS instruments and data processing algo-
rithms [33].
All the above-mentioned methods are, in general, un-
targeted techniques aiming to identify and quantify all the 
proteins in a complex sample compared to another, usu-
ally diseased proteome versus control. Nonetheless, some 
of these methods may be used for targeted approaches or 
even for absolute quantification, being the gold standard 
of MS-based absolute quantification the multiple reaction 
monitoring (MRM) method [34].
There are numerous studies employing these tech-
niques in psychiatric research. Initially, the great majority 
of the studies were performed in post-mortem brain tissue 
and it is easy to find large screenings in several brain areas, 
such as frontal [35] and prefrontal cortex [36]; the corpus 
callosum [37]; the temporal lobe [38] or the hippocampus 
[39] (citations as examples, for an extensive review refer 
to [14]). Later on, other tissues [40, 41] or cell populations 
[42] and body fluids (Tables 1 and 2) or even animal mod-
els (e.g. [43, 44]) started to raise interest in the search of 
the pathophysiological basis of this disease, but especially 
in the quest for biomarkers.
As SCZ is considered a brain disease a natural way of 
studying it would be through the brain, and when talking 
about proteomics this means post-mortem brain tissue 
[45], as above mentioned. Nonetheless, and although very 
informative, post-mortem brain tissue has its drawbacks, 
as the susceptibility of confounding factor, namely medi-
cation or age and chronicity of the disease, besides the fact 
that the tissue is static, with no possibilities of being ma-
nipulated, disturbed or having longitudinal samplings [46, 
47]. Thus, current proteomic studies have been focusing in 
peripheral tissues or fluids, and integrating all these anal-
yses a more complete picture of the disease is expected to 
emerge in what concerns onset, progression and respon-
siveness [47].
Biomarker discovery in CSF
It is expected that the quest for biomarkers may be per-
formed as closely as possible to the source of the question be-
ing studied, and in what concerns neuropsychiatry (and neu-
rology in general) and the diagnostic purpose of biomarker 
discovery, the closest to the living brain that it is possible to 
get is to analyze the cerebrospinal fluid (CSF)[11].
CSF, or liquor, is a body fluid that occupies the ventric-
ular system surrounding the brain and the spinal cord, and 
is rich in molecules, such as proteins, peptides and small 
metabolites, that are either products of or have physiolog-
ical properties in the central nervous system (CNS) [55, 
56]. It is estimated that at a given time each person has 150 
mL of CSF, with a daily production turn-over of 500 mL, 
meaning that CSF is extremely dynamic and characteristic 
of the physiology at the moment of collection [11].
The protein content of CSF may be very variable and 
is estimated to have values between 0.18 to 0.58 g/L [57], 
which corresponds to about 0.5% of the concentration of 
proteins in serum [58], and presents a high dynamic range 
with proteins like albumin accounting for much of the 
protein content [59]. Nonetheless, even the total amount 
of protein present in the CSF has diagnostic potential, for 
instance an increase in protein content in the liquor is ob-
served in infection or multiple sclerosis [57].
CSF is collected by means of a lumbar puncture, where 
a small volume of the liquor is collected for clinical analysis 
(for instance for protein and glucose levels assessment, cell 
counts and microscopic examination, or culture) [57] and 
it can be collected using controlled and standardized proce-
dures which help reducing variability at the collection step 
[59]. CSF collection is considered a fairly invasive proce-
dure, implicating that new collections, either to have more 
sample volume or to perform longitudinal studies, are not 
easy to perform. Thus, proteomic analysis of CSF is fea-
sible but implicates robust and sensitive techniques [11].
After a careful search in public repositories (namely 
PubMed and Web of Knowledge) and with bibliographic 
mining, we were able to locate 8 schizophrenia studies us-
ing MS-based proteomics approaches to study the CSF as 
documented in Table 1. From the analysis of this table it is 
possible to understand that the first study of the kind was 
performed in 2003, and that several studies followed until 
2012. Since then we were not able to find other studies 
using mass spectrometry in CSF of schizophrenic patients.
The majority of these proteomic studies were per-
formed using 2-DE followed by MALDI-TOF-MS [48, 
50, 53] or by using SELDI-TOF-MS [40, 49, 51, 54]. Only 
one study [52] uses label-free MSE, an approach where the 
fragmentation spectra of virtually all the peptides resulting 
from protein digestion is acquired [60].
In general, a low number of proteins are identified in 
these studies, but some of the studies claim to be able to 
distinguish between schizophrenia and healthy groups 
using either the relative quantification of the detected 
features (exact mass and retention time) in MSE analysis 
[52]; or by using the up-regulation of a VGF-derived pep-
tide and the down-regulation of transthyretin, in this case 
achieving a specificity of 95% and a sensitivity above 80% 
in distinguishing SCZ from controls, yet being unable to 
distinguish it from patients in the prodromal state [49]. 
Several other studies also proposed some molecules as 
SCZ biomarkers, such as Wan et al. [50], which propos-
es transthyretin and apolipoprotein E as possible markers 
for diagnosis and optimal treatments; or Martins-de-Souza 
and colleagues, which propose apolipoproteins E and A1 
and prostaglandin-H2 D-isomerase as a putative panel of 
biomarkers in CSF for SCZ diagnosis [53]. In another very 
complete study of CSF, apolipoprotein A1 was found to 
be down-regulated in CSF, liver, red blood cells (RBC), 
serum, and in post-mortem brain tissue regardless of the 
treatment and chronicity of the disease, evidencing that 
some alterations in CNS can have correlated results in sys-
temic organs and fluids [40].
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Table 1. Proteomic studies of schizophrenia and schizophrenia biomarker discovery using mass spectrometry in CSF.
Year Number of 
Samples
Method Diagnosis Treatment No. proteins Altered Proteins Altered 
Pathways
Reference Observations
2003 10 SCZ; 10 CTR 2-DE/ MALDI-MS Schizophrenia - Total ID: 54 APOA4 ↓ Lipoprotein 
metabolism
[48] Haptoglobin, fibrinogen, comple-
ment component 3 and Gc-globulin 
were also altered, but not statistical 
significant
2006 58 first-episode SCZ; 








Drug naive - 40-amino acid 
VGF32-62 peptide 
↑ and TTHY↓
- [49] Different distribution between SCZ 
and CTR; 80% sensitivity and 95% 
specificity in the validation study
2006 35 SCZ; 36 CTR 2-DE/ MALDI-MS Schizophrenia Chlorpromazine Total ID: 80 APOE↓; TTHY 
tetramer↓; TRFE↓; 









2007 54 first-episode SCZ; 





dromal state of 
psychosis 
Drug naive - VGF (VGF23-62)
peptide ↑; TTHY↓;
Metabolism [51] Significant differences between CTR 
and SCZ; no significant differences 
between IPS and CTR, and IPS to SCZ






Drug naive Total ID: 77 - - [52] Clear difference between CTR and 
SCZ observed in PLS-DA scores
2008 41 SCZ; 40 CTR SELDI-TOF-MS First episode para-
noid schizophrenia 
or Brief psychotic 
disorder
Drug naive Total ID: 1 APOA1↓ Neuronal and 
glia metabolism
[40] Also decreased in the liver, RBC, se-
rum and post-mortem brain samples 













[53] 540 protein spots in SCZ 2-DE; 542 in 
CTR; 468 matched spots







Total ID: 15 Aβ- 
peptides
sAPPα↑; Aβ1-42↓ Neuronal plastic-
ity and survival
[54] -
SCZ: Schizophrenia; CTR: Control; LC: Liquid chromatography; MS: Mass Spectrometry; TOF: Time-of-flight; 2-DE: Two-dimensional gel electrophoresis; MALDI: Matrix-assisted laser desorption/ionization;
DEP: Depression; OCD: Obsessive compulsive disorder; AD: Alzheimer’s disease; SELDI: Surface-enhanced laser desorption/ionization; IPS: Prodromal state of psychosis; H-NMR: Proton nuclear magnetic resonance; PLS-DA: Partial Least Squares Discrimi-
nant Analysis
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Given all this, CSF is a truly valuable source of infor-
mation from where many potential biomarkers may arise, 
and of clues to understand the pathophysiology of SCZ, 
as it is documented in the described studies. Nonetheless, 
we believe there is still space for the non-targeted large 
screening approach in the CSF especially due to the con-
stant improvement of the mass spectrometry field. Even 
so, this fluid does not meet entirely the definition of a good 
fluid for routine clinical evaluations because its collection 
is invasive and the amount of sample is relatively small 
[61]; the study and validation of possible biomarker candi-
dates will probably be translated to more readily available 
biological fluids.
Biomarker discovery in Peripheral fluids
For over a decade peripheral fluids’ analyses, for disease 
investigation and biomarker discovery in particular, have 
increased in the psychiatric field [12]. As shown in Table 
2, blood-based analysis account for the majority of such 
studies, especially with the analysis of serum and plasma, 
although blood cells’ analysis is growing in interest (Table 
3) [74]. The rationale behind this is that, even if psychiatric 
disorders are brain diseases, its consequences can be de-
tected throughout the entire body; and, most importantly, 
the access to fluids like blood is considerably easier than 
the access to the living brain or even to CSF. 
It is a long standing fact that there is strong integration 
of brain and a variety (if not all) of physiological conditions 
altering the contents of body fluids, where the classic ex-
ample is the “fight-or-flight reflex” [75] in which there is 
a strong interplay between the hypothalamic-pituitary-ad-
renal axis. It has been demonstrated that there are dy-
namic changes correlating changes in brain and blood and 
vice-versa [47, 74], and, in the case of SCZ, some changes 
in hormones, cytokines or growth factors can be replicated 
both in brain and blood stream [74, 76].
This whole-body approach of the biology of psychiat-
ric disorders is starting to provide some answers; in recent 
studies it is stated that molecular signatures may be found 
in the periphery, especially in circulating blood, as are the 
examples of studies for schizophrenia [77, 78], major de-
pressive disorder [79], and bipolar disorder [80]. 
In summary, peripheral fluids present themselves as 
extremely valuable for psychiatric research and biomark-
er discovery and validation, once molecular changes due 
to the disease causes, chronicity or drug responses, for in-
stance in proteins’ levels or PTM patterns, may be mea-
sured directly in the blood (Table 2 and 3), or even in less 
conventional fluids as saliva or sweat (Table 3). The col-
lection of these fluids presents the valuable advantage of 
being non-invasive (urine, saliva, sweat, tears…) or min-
imally invasive (blood), allowing for multiple collections 
and the collection of meaningful amounts for the analyses 
to be performed. On the other hand, these fluids also pres-
ent challenges, such as the extremely high dynamic range 
of plasma or serum, where a dozen of proteins represent 
more than 90% of the protein content; the more laborious 
procedure to obtain pure blood cell specimens [81]; or the 
still not standardized collection of fluids like saliva, sweat 
or tears [82-84]. 
Given all this, an extensive search for SCZ mass spec-
trometry-based proteomic studies in peripheral circulating 
fluids was performed. On Table 2 are presented the stud-
ies published on blood serum and plasma, spanning from 
2006; after this search 7 studies on serum of patients with 
SCZ and 6 on plasma were found. The preferred quantita-
tive method of analysis of the serum samples was label-free 
MS, using LC-MSE [62-64] or MS1 signal intensity [65-
67]. On the other hand, from the 6 studies in plasma, 5 
used 2-DE-MS analysis [50, 69-72] and one study using 
targeted mass spectrometry MRM technique to quantify 
42 plasma proteins [73]. 
As expected, some of the studies used depletion of 
the most intense proteins prior to the analysis [64, 65, 
68]; some studies also focused on PTM analysis, namely 
phosphoproteins and differential phosphorylation pat-
terns [64, 67]. Zhou et al focused on the peptidome of se-
rum by using magnetic beads to capture the peptides, iden-
tifying 10 altered peptides, one of which being identified as 
a fragment of fibrinopeptide A with a receiver operating 
characteristic (ROC)  analysis showing an area under the 
curve of 0.981 between SCZ and controls, and 0.999 for 
schizophrenia and other chronic diseases [66]. Al Awan 
and colleagues prepared an integrative study, analyzing 
proteomics and metabolomics data suggesting a profile 
signature of the pathology found in serum [67].
Mass spectrometry proteomics studies of SCZ using 
less conventional fluids as specimens for analysis are pre-
sented on Table 3. The use of blood cells, for instance, has 
the advantage of circumventing the dynamic range issue of 
serum and plasma. Using such methods total populations 
of peripheral blood mononuclear cells (PBMC), specific 
lymphocytes subpopulations as T-cells (both stimulated or 
unstimulated), or red blood cells (RBC) obtained from the 
blood stream of SCZ patients have already been studied.
[41, 85, 86] One study using saliva [87] and another using 
sweat [88] have already been performed in the context of 
SCZ proteomics.
Red blood cells are an easily accessible cell population 
of the blood stream, and taking advantage of it Praba-
karan et al analyzed RBC proteins using 2D-DIGE meth-
odology, being able to find 8 altered proteins, 4 of which 
related to oxidative stress, corroborating earlier findings 
in post-mortem brain tissue and validating blood cells as 
good specimens for the search for SCZ biomarkers [41].
Studying T-cells from minimally medicated SCZ pa-
tients α-defensins were found altered and able to discrimi-
nate the 2 groups (SCZ and control) in a PCA analyses; this 
differential expression was further validated by an ELISA 
assay finding the up-regulation of α-defensins both in af-
fected and unaffected monozygotic twins, indicating these 
7Santa et al.
International Journal of Clinical Neurosciences and Mental Health 2017; 4(Suppl. 3):S05
Table 2. Proteomic studies of schizophrenia and schizophrenia biomarker discovery using mass spectrometry in blood serum and plasma.
Year Number of 
Samples




2007 22 first episode 
SCZ; 23 CTR
Label-free LC-MSE Paranoid 
schizophrenia
- Total ID: 1709 
(50% Conf); 232 
(95% Conf*)
zinc finger , BTB domain-containing 
protein 38 less abundant; APOA1 
most abundant
- [62] Technical paper




























Drug naive Detected: 694; 

























[64] Of the 72 proteins showing 
phosphorylation changes, 
59 showed no significant 
changes in expression level;  
FCN3 and  RET4  validated 
by ELISA
2012 Proteomics 
sample set: 10 
SCZ; 10 CTR; 
Validation 





Schizophrenia Proteomic sample set: drug-
naïve; Validation sample set: 
29 drug-naive; 18 drug-
naive during 8 weeks;
Total ID: 1344; 
192 used for 
PLS-DA (27 SCZ-
related)
CO8B↑; CD5L↑; DOPO↑; IGHG4↑; 
IGHM↑; KNG1↑; PI16↑; PGRP2↑ 
ITIH4↑; PLTP↑; IPSP↑; IGK@ protein↑; 
IGL@ protein ↑; AMPN↓; APOC2↓; 
APOF↓; C4BPB↓; APOL1↓; FA7↓; 
GGH↓; ICAM2↓; ALS↓; isoforms 2 of 





[65] Validation set: were divided 
in three groups and received 
four weeks treatment with 
clozapine (26 patients); 
chlorpromazine (15 patients) 
or other drugs such as ris-
peridone (6 patients)
2014 Model: 166 SCZ; 
201 CTR; 
Validation: 76 
SCZ; 103 CTR 











Drug naive Total ID: 10 al-
tered peptides
Fragment of Fibrinopeptide A   m/z: 
1206.58  
AUC of Roc above 0.98
- [66] -















11 protein ions 
from TiO; and 5 
from C8
m/z 3177 suggested to be  frag-
ment of Apolipoprotein A1
- [67] -







Drug naive Significantly 
different:  91 
protein peaks
N-terminal fragment of fibrinogen ↓ - [68]
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Table 2. Proteomic studies of schizophrenia and schizophrenia biomarker discovery using mass spectrometry in blood serum and plasma. (cont.)
Year Number of 
Samples
Method Diagnosis Treatment No. proteins Altered Proteins Altered Pathways Reference Observations
PLASMA
2006 19 SCZ 2-DE/ MALDI-
MS
Schizophrenia Chlorpromazine Total ID: 56 TTHY tetramer ↑ - [50] Responders vs non-responders in 
pre and post-treatment
2006 22 SCZ; 20 CTR 2-DE/ MALDI-
TOF-MS
Schizophrenia Clozapine Total ID: 66; 
Significantly 
different: 7
HPT-α2 chain↑; HPT-β chain↑; 




[69] To exclude drug treatment effect, 
plasma from 11 SCZ patients was 
collected before medication and 
after 2 months of medical treat-
ment (clozapine)
2007 25 SCZ;  9 CTR 2-DE/ MALDI-
MS
Schizophrenia 8 patients w/ Chlor-
promazine; 8 pa-
tients w/ Clozapine
Total ID: 7 APOA1↓ Lipoprotein [70] Adult male  Sprague-Dawley 
rats: 9 rats w/ Clozapine; 9 rats w/ 
Chlorpromazine; 8 rats received 
ddH2O; Total proteins ID: 29; 
Significantly different: 18; APOA1, 
APOA4, APOAE ↑ w/ Chlorproma-
zine
(negative control) 
2007 42 SCZ; 46 CTR 2-DE/ MALDI-
MS
Schizophrenia Chlorpromazine Total ID: 20; 
significantly 
different: 6









Schizophrenia Risperidone Total ID and 
altered: 18
APOA1↑; C4B↑; CFB↑; NEB↑; 
C8B↑; ZN185↑; PLMN↑; 
HEMO↑; HNMT↑; GBP1↑; 
FGG↑; TRFE↑; ALEX↓; RET4↓; 
K1C9↓; K2C1↓; VINC↓; GELS↓
Metabolism [72] Investigate changes in protein 
expression before and after treat-
ment













gene, Valproic acid, 
Quetiapine, Antide-
pressant (BD)
Total ID: 42; 
significantly 
different: 19
ANT3; APOA1; APOA2; APOA4; 
APOC1; APOC2; APOC3; 
APOC4; APOL1; C1QC; CFB; 
C3; F13B; FCN3; HSP70 escort 
protein 2; HRG; KLKB1; PEDF; 
RET4
(Patients – SCZ and BD vs. 
Control)
- [73] Significant dissimilarities
between BD and SCZ patients: 
A2AP, ANT3, APOB, APOD
and APOF
*Conf: Confidence of Identification. For other abbreviations see Table 1 footnotes.
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Table 3. Proteomic studies of schizophrenia and schizophrenia biomarker discovery using mass spectrometry in less studied biological fluids, like peripheral blood cells, sweat and saliva.
Year Number of 
Samples
Method Diagnosis Treatment No. proteins Altered Proteins Altered Pathways Reference Observations
2014 
(Saliva)
32 SCZ; 17 BD; 31 







- Total ID: 8 DEF1↑; α-defensin-2↑; DEF3↑; 
DEF4↑; S10AC↑ ; CSTA↑; CSTB gluta-
thionyl↑; CSTB cysteinyl↑;
(Patients – SCZ and BD vs Control)
















1st set Total ID: 
150;
2nd set
Total ID: 185; 
MRM: 30
ZA2G↑; ANXA5↑; ARG2↑; BLMH↑; 
CALL5↑; CASPE↑; CDSN↑; CSTA↑; 
DCD; Desmoglein↑; DJ-1↑; 
G3PDH↑; KLK11↑; KRT10; PRDX1↑; 





mal process; Response 
to stimulus
[88] Altered protein: MRM 
results for sweat pep-
tides/proteins chosen 
from Scaffold list after 




15 SCZ; 15 CTR 
(SELDI-TOF)/ 




Schizophrenia - Total ID: 108 
peaks
α-defensins↑ Immune response [86] -
2011 
(PBMC)
19 SCZ (12 first-
onset; 7 chroni-
cally ill);  19 CTR
LC-MSE Schizophrenia 12 Drug naïve; 7 Anti-






naïve SCZ and 
CTR
Unstimulated PBMCs: CNDP2 ↑; Un-
characterized protein KIAA0423↑; 
LDHB↑; COTL1↓; GPI↓; HSP72↓;
Stimulated PBMCs: ALDOC↑; GAP-
DH↑; HNRPK↑; LDHB↑; MYH14↑; 
MYH15↑; NAMPT↑; PGK1↑; PPIA↑; 
TPIS↑; PKLR↑; PGAMA4↑; CH60↓;
Glycolytic pathway, Im-
mune response
[85] Validation cohort: 
8 drug naive; 7 
antipsychotic-treated, 




20 SCZ (13 treated 
/ 7 naïve); 20 CTR
2D-DIGE / LC-
MS/MS




Total ID: 418; 
Significantly 
different: 8
SBP1↑; GSTA3↑;  PRDX5↓; HS71L↓; 
ALBU↓; APOA1↓; SPTA1↓; ACTB↓
Oxidative Stress [41] -
ELISA: Enzyme-Linked Immunosorbent Assay; IMAC: Immobilized metal affinity chromatography; CD: Chronic disease; MRM: Multiple reaction monitoring; BP: Bipolar disorder; HPLC: High-performance liquid chromatography; ESI: Electrospray Ionization; 
2D-DIGE: Difference gel electrophoresis
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proteins as possible early indicators of SCZ risk [86]. In 
order to study stimulated and unstimulated PBMCs from 
drug-naïve SCZ and control individuals, Herberth and 
colleagues chose a LC-MSE and were able to quantify hun-
dreds of proteins [85]. From these, 18 proteins were found 
to be statistically altered between first onset SCZ patients 
and controls, with more pronounced alterations when the 
cells are stimulated; this phenotype was found to be res-
cued when a cohort of chronically ill medicated patients 
was analyzed, suggesting that these proteins are modu-
lated by medication and may have diagnostic potential in 
first-episode SCZ patients.
The study using saliva as specimen for the analysis of 
samples from SCZ and bipolar disorder (BD) found sev-
eral proteins changed between patients and controls, but 
was not able to find statistically meaningful differences be-
tween SCZ and BD patients [87].
Although studies relating SCZ and sweat odors span 
back to 1969 [89], and sweat has already been used to 
analyze the distribution of antipsychotics, like clozapine 
[90], only one proteomics study was found that searched 
for SCZ biomarkers in sweat [88]. In this study spectral 
counting label-free approach was used to compare several 
pooled samples from SCZ and control individuals and se-
lect 30 proteins to be validated by targeted MRM-MS; 17 
proteins showed a differential expression of at least 2-fold 
between the SCZ and control pooled samples.
General Overview and challenges
Proteins found to be changed in SCZ patients on peripher-
al fluids were gathered on Figure 1. In this figure, proteins 
proposed as altered in the published studies were orga-
nized by biological fluid; if the same protein was found to 
be changed in more than one biological fluid it was listed in 
a “common proteins” column, meaning that there are more 
evidences for the regulation of those particular proteins in 
the peripheral fluids of patients with SCZ.
In total, there are dozens of differently expressed pro-
teins which were found changed between the 25 projects 
analyzed in this review (Tables 1, 2 and 3). From all these 
proteins only 18 of them were found modulated in at 
least 2 different fluids; and although in many cases this 
fact may act as a preliminary validation of the potential 
of those proteins as SCZ biomarkers, in some of the cas-
es the results in the different studies are not uniform, 
having opposite differential expressions, as is the exam-
ple of protein tetranectin which was found upregulated 
in the CSF study [50] and downregulated in the serum 
study [64]. On the other hand, some other proteins have 
been consistently and repeatedly identified as changed 
in several fluids, as transthyretin which has been found 
downregulated in CSF [50, 51, 53] and plasma [69], but 
upregulated in plasma after medication [50].
From the analysis of this integrative Figure 1, it is 
possible to note that, from 18 “common proteins”, 7 be-
long to the family of apoliproteins, and these represent 
some of the most replicated modulated proteins in pe-
ripheral fluids in SCZ. Nonetheless, all the other proteins 
presented in this figure have potential to be further stud-
ied, validated and possibly integrated in a panel for SCZ 
diagnosis, prognosis or even treatment response predic-
tion; even though these large screening approaches still 
face many challenges.
Overall, this data overview on peripheral biomarkers 
of SCZ is very encouraging in the pursuit for a proper 
biomarker panel for the disease. Nonetheless, the fact that 
SCZ is a very  complex and heterogeneous disorder should 
always be taken into account [91]. Moreover, it is even 
suggested that further knowledge of the disease patho-
physiology and higher stratification of the patients may 
be needed, where biological and clinical markers may help 
distinguish different subsets of SCZ patients and may not 
have the classical diagnostic potential (SCZ versus non-
SCZ) [92, 93].
Additionally, some important factors are frequently 
overlooked in screening studies, such as comparing if the 
candidate proteins show similar patterns in other psychi-
atric diseases, meaning that those alterations may arise 
from common phenotypes of the pathologies and not be 
an indication of the unique traits [93], which is the final 
goal of a biomarker.
Another challenge in the research of psychosis bio-
markers is the sample set and patient recruitment that is 
necessary for all studies, but in particular for these large 
screening studies. First-onset drug-naive schizophrenia 
individuals are the preferred subjects of study and their 
recruitment has a low rate, leading to longer project du-
ration and consequently longer storage times and higher 
variability [94, 95]. On the other hand the recruitment 
of chronically ill medicated patients is easier but comes 
with the disadvantage of making it necessary to clearly 
distinguish drug from disease-related changes, which is 
not as straightforward as it may seem; it is a factor that is 
many times disregarded in previous studies, explaining to 
some extent the low reproducibility of the findings [96].
Thus, the use of well established, well-matched sub-
pools of disease and control subjects, with enough repli-
cates to generate powerful analyses should be used. Another 
important step is the validation of the interesting findings 
with different methodologies and most importantly with 
different and bigger cohorts of individuals. [14].
A primary challenge in the search for biomarkers is 
the easy access to sufficient amounts of high-quality body 
fluid [97], for instance the use of CSF. Although it is still 
the circulating fluid that more closely reflects pathophys-
iological alterations caused by neurological disorders, and 
although it is in communication with cerebral extracel-
lular fluid and is less hampered by confounding factors, 
problems could be associated with CSF sampling as it is 
still an invasive procedure [97] although it tends to be-
come more routine and safe. 
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Moreover, blood collection standardization is a neces-
sary step in any blood study aiming to report findings on 
potential biomarker. In order to decrease study variation, 
blood collection protocols should have all identical time of 
collection, must use the same coagulants and blood pro-
cessing methods, where these methods should be exten-
sively and accurately described [93]. Furthermore, stan-
dardized collection also allows investigators to replicate 
studies with samples that match the initial pilot data. 
In summary, the idea that the establishment of standard 
operating procedures (SOP) for each step of the process, 
comprising collection, handling, preparation and storage is 
appearing as mandatory in order for the results of the differ-
ent research centers to be integrated and the identification 
of powerful biomarkers may be reached [98]. Moreover, 
the publication of entire datasets from these exhaustive pro-
teomic studies, rather than just positive findings, is crucial 
for the mandatory integration of all information being ac-
quired by the scientific community at the present [14]. 
Future Perspectives and conclusion
This review covers a compilation of proteomics studies 
performed on body fluids of schizophrenia patients using 
mass spectrometry. Comparative proteomics analysis is ex-
tremely important and of the highest clinical interest as it 
may reveal potential biomarkers for diagnosis and choice 
of therapy, refining prognosis and treatment prediction. In 
certain pathologies it is not the presence of certain proteins 
per se that makes them markers but rather their expression, 
the alterations in expression as well as their state. More-
over, in many cases it is not just one single protein but a set 
of proteins that is indicative of a certain disease. In this way, 
emerging proteomic platforms have facilitated the identifi-
cation of several biomarker candidates by the simultaneous 
measurement of thousands of proteins.  Before proteomic 
tools can be routinely used in the clinical laboratory, further 
work is necessary to enhance the performance and repro-
ducibility of established proteomics approaches. 
SERUM
CD5L; APOD; FETUA; K2C6B; SRBS1; NUCB1; 
ALS2; IBP3; MAST1; C4BPA; FHR3; ITIH3; CO6; 
AGRE1; CAH1; LRRC7; FR1L6; KI21B; 
KIF27;MYOF;FIBA; CCD57; SMC1A; K1C14; PHLD; 
LIFR; XIRP1; WDR19; SMC4; SAGE1; CO8B; DOPO; 
IGHG4; KNG1; PI16; IGK PROTEIN; AMPN; APOF; 
C4BPB; FA7; GGH; ICAM2; LBP; PROS; ZNF57; 
fragment of Fibrinopep�de A; N-terminal 
fragment of ﬁbrinogen
 PBC
CNDP2; COTL1; GPI; HSP72; LDHB;ALDOC; 
CH60; GAPDH; HNRPK; MYH14; MYH15; 






VGF-3262; ALBU; A1AG2; IG GAMMA; 
IG KAPPA; PTGDS; TGFR1; CCDC3; 
sAPPα; Aβ142; APOJ
SWEAT
ZA2G; ANXA5; ARG2;BLMH; 
CALL5; CDSN; DCD; 
Desmoglein; DJ-1; G3PDH; 
KLK11; KRT10; PRDX1; PIP; 
 PLASMA
HPT-α2 chain; HPT-β chain; AMBP; 
ANT3; VTDB; CFB; SAMP; NEB;C8B; 
ZN185; PLMN; HEMO; HNMT;GBP1; 
FGG;ALEX; K2C1; VINC; GELS; ADT3; 
APOC3; APOC4;C1QC; CFB;C3; 
HSP70; HRG; KLKB1; PEDF





















Figure 1. Possible circulating biomarkers. Summary illustration depicting the proteins found altered in the several studies of each fluid. The 
uniquely altered proteins for each fluid are represented, as well as the proteins found altered in at least 2 different biological fluids.
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Sufficient and high-quality sample, sample collection 
standardization and type of approach are some of the 
methodological limits of the existing studies that should be 
overcome or improved. 
The use of multidisciplinary approaches in SCZ studies 
is appearing as mandatory strategy. Due to the multifactori-
al picture of schizophrenia, possibly one type of approach is 
not sufficient to discover one specific biomarker. A combi-
nation of imagining techniques, neuropsychology, electro-
encephalograms (EEGs) and proteomic approaches should 
be interesting and challenging to identify a multifactorial 
signature of the disease [95]. Additionally, such a combined 
approach may help to overcome present difficulties in bio-
marker discovery such as the issue of antibody availability 
and lack of comprehensive proteome coverage  [95].
The exploration of less classical peripheral fluids, like 
sweat, saliva or urine, are also starting to arise and will 
probably be studied more intensely in the future once they 
present themselves as easily accessible fluids, although still 
lacking standardization of collection and also of process-
ing. Urine is an easily accessible biological fluid, extensive-
ly studied in many fields but still not explored in the pro-
teomics of psychiatry; a possible gap of the investigation 
in the field. 
Since we are in the era of Bioinformatics current stud-
ies have been focused on protein expression and pro-
tein-protein interactions around certain genes in order 
to fill the gap between genomics and proteomics [97]. Al-
though most of the published studies are promising, they 
are based on small sample size, have low power or have not 
been replicated, which can interfere with further research. 
Multi-site studies, data sharing, multivariate biomarker 
studies, and combined use of “omics” data are some alter-
natives to overcome these methodological limitations [99]. 
Moreover, there is a critical need for complementing and 
integrating studies with different profiling methods (pro-
teomics, transcriptomics, metabolomics). 
Altogether, mass spectrometry offers the most holistic, 
integrated system for clinical analysis of patient samples, 
seeking both known and unknown biomolecules (Tables 1 
2 and 3). Mass spectrometers can analyze proteins, peptide 
fragments, small molecules, antibodies, metabolites, and 
lipids. This collection, obtainable from a single platform, 
can generate the total sum of a patient’s physiological state 
needed for quick and proper diagnosis, exact treatment 
selection, and therapeutic monitoring [23]. The categori-
zation of patients based on proteomic biomarker profiles 
for optimized treatment is a form of personalized medicine 
that should be aimed for a nearby future.
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